The Journey Has Just Begun For LAG-3 Therapeutics

 
• By Jo Shorthouse

Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.  

Journey
• Source: Shutterstock

More from Innovation

More from In Vivo